US20060127375A1 - Cryopreservation of human red blood cells - Google Patents
Cryopreservation of human red blood cells Download PDFInfo
- Publication number
- US20060127375A1 US20060127375A1 US11/334,950 US33495006A US2006127375A1 US 20060127375 A1 US20060127375 A1 US 20060127375A1 US 33495006 A US33495006 A US 33495006A US 2006127375 A1 US2006127375 A1 US 2006127375A1
- Authority
- US
- United States
- Prior art keywords
- red blood
- blood cells
- composition
- concentration
- reagents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
Definitions
- Blood is composed of plasma and cellular constituents and plays a prominent role in several key physiological systems of the human body, including immunology, hemostasis, and tissue oxygenation. Movement of the respiratory gases oxygen (O 2 ) and carbon dioxide (CO 2 ) is the chief function of erythrocytes or red blood cells. This facilitated movement Of O 2 and CO 2 is carried out by hemoglobin, an iron-containing, multi-subunit protein contained within red blood cells. The necessity for encapsulating hemoglobin within the red blood cell is twofold. First, hemoglobin has very specific binding parameters to ensure delivery of these critical molecules to the proper sites. By regulating the concentration of cofactors and free ions, the red blood cell provides the proper environment for optimum uptake and release of O 2 . Secondly, free heme has toxicity effects on both the renal and hepatic systems and can lead to conditions such as hemoglobinuria.
- the red blood cell structural components which confine the hemoglobin are comprised of the membrane bilayer and the cytoskeleton.
- the membrane itself contains choline and amino phospholipids, cholesterol, and integral membrane proteins.
- the cytoskeleton Along the inner surface of the membrane lies the cytoskeleton.
- This mesh-like skeleton is composed of long, filamentous spectrin molecules joined together at foci of F-actin and protein 4.1 complexes.
- This cytoskeletal mesh is linked to the membrane through protein-protein interactions such as the ankyrin/protein 4.2 mediated connection of spectrin and the integral membrane protein Band 3, and possibly via direct protein-lipid interactions. Through these connections, the cytoskeleton provides the red blood cell its stability and shape.
- red blood cell In the absence of proper binding within the cytoskeletal mesh or the connection of the cytoskeleton to the membrane, a critically weakened red blood cell results.
- Several human diseases have been identified stemming from either an absence of a specific protein or a defective protein interaction. Most of these defects lead to morphologically abnormal red blood cells and severe hemolytic anemias.
- red blood cell units are stored in citrate phosphate-dextrose at 4° C.
- erythrocytes are separated and stored by various methods, generally as a unit of packed erythrocytes having a volume of from 200 to 300 ml and a hematocrit value of 70 to 90.
- these cells may be stored no longer than 42 days.
- 70% of these stored cells remain in circulation following transfusion, true O 2 delivery capability has not been demonstrated.
- ATP adenosine triphosphate
- 2,3-DPG 2,3-diphosphoglycerate
- the concentration of ATP after a brief initial rise, progressively declines to between 30 and 40% of its initial level after six weeks of storage. Morphological changes occur during storage, ultimately leading to the development of spicules which can bud off as vesicles, radically changing the surface-to-volume ratio of the cells and their ability to deform on passing through narrow channels.
- the fluidity of the cell membrane of red cells which is essential for the passage of red cells through the narrow channels in the spleen and liver, is loosely correlated with the level of ATP.
- concentration of ATP and the morphology of red cells serve as indicators of the suitability of stored cells for transfusion.
- the second method is frozen storage at ⁇ 80° C. using 40% (w/v) glycerol as a cryoprotectant.
- this additive penetrates the membranes of many biological cells and possesses unwanted properties when infused into humans. While this method can be used for up to 10 years of storage, the glycerol must be washed out prior to transfusion. The washing procedure utilizes costly equipment and is time and labor intensive. Additionally, a significant level of hemolysis (10-15% typically) occurs during the wash procedure. Finally, since this procedure is also considered to compromise the sterility of the red blood cell units, post-wash storage is significantly limited. Consequently, this method of storage is only used for blood with extremely rare factor types and autologous and directed donation units which will not be used within a 42 day period.
- dehydration injury is believed to be the result of membrane stresses leading to membrane rupture. This form of injury can be prevented by the addition of solutes at a multi-molar concentration so that the amount of ice formed is insufficient to result in damaging cell dehydration.
- cryoprotective For many years it has been known that certain molecules may be cryoprotective. It is necessary for these penetrating cryoprotectants to reduce the amount of extracellular ice formed and thereby reduce cell dehydration, while at the same time increasing the intracellular concentration to make intracellular crystallization less likely. Such a solute, to be useful, must is be non-toxic at high concentration and must freely penetrate the cell. Both glycerol and dimethylsulfoxide (DMSO) have been used for this purpose. Glycerol is remarkably non-toxic at high concentrations but penetrates cell membranes slowly and is therefore difficult to introduce and remove. Dimethylsulfoxide penetrates rapidly but becomes increasingly toxic as concentrations exceed 1 M (about 7%).
- DMSO dimethylsulfoxide
- PVP polyvinylpyrrolidone
- HES hydroxyethyl starch
- red blood cells in order to prolong the storage of red blood cells it is necessary to store the cells or treat them in some manner that prevents a decline in ATP, and, if possible, 2,3-diphosphoglycerate (2,3-DPG), in addition to protection against ice crystal damage.
- 2,3-DPG 2,3-diphosphoglycerate
- such solutions contain phosphate, glucose, and adenine which function to prolong shelf-life by maintaining the level of ATP in the cells.
- glycolytic activity is enhanced in red blood cells if the intracellular pH measured at 4° C. is about 7.4.
- the effective osmolality of the suspending solution is another factor of importance in extending red cell storage time. It has been shown that hypotonically induced increases in mean cell volume substantially reduce hemolysis and improves red cell morphology during storage.
- red cells which are normally bi-concave disks, can swell to nearly twice their normal volume at an external osmolality of approximately 170 mOsm before they hemolyze. If the additive solution is too hypotonic, the red cells will burst (hemolyze). As a result, solutions that are too hypotonic cannot be used. While maintenance of ATP and 2,3-DPG are generally thought of with reference to 4° C. storage, maintaining the concentration of these metabolites is important for post-thaw storage.
- the goal of extended red blood cell storage is to maintain the metabolic and morphologic characteristics so that the in vivo parameters (oxygen delivery capacity and circulatory half-life) are comparable to fresh, non-frozen red blood cells. Additionally, the level of hemolysis during the storage cycle must remain within acceptable levels to allow direct transfusion of the thawed red blood cell unit without complications from hemoglobin toxicity. These goals can be accomplished using the method of this invention.
- the method described herein provides the advantages of both currently approved storage methods—extended storage time in the frozen state and immediate availability as in refrigerated storage.
- the invention described herein addresses the noted problems of storage, morphological changes, metabolic changes, and long term functional effectiveness of red blood cells. Further, the present invention achieves unexpected and surprising results in the preservation of red blood cells through treating with the compositions and methods of this invention and which previously would have been considered impossible.
- This invention provides a method for storing red blood cells in the frozen state at subzero temperatures ( ⁇ 10° to ⁇ 193° C.) such that the resulting thawed red blood cell unit contains viable cells. Specifically, this is accomplished through a combination of biochemical stabilization and cryoprotectant solution.
- a biochemical stabilizing reagent is one that provides no traditional cryoprotection, in that it alone does not diminish the formation or quantity of ice during the freezing process at the concentration used.
- the combined cryoprotectant is solution is composed of transfusable cryoprotective reagents
- the resulting thawed red blood cell unit is directly transfusable.
- incorporating biochemical stabilizing technology allows cryopreservation of red blood cells utilizing concentrations of cryoprotectants lower than would be necessary in the absence of biochemical stabilization.
- Biochemical stabilization involves the addition of reagents which target specific red blood cell components and biochemical pathways susceptible to damage during the freeze/thaw cycle. Stabilization with these reagents renders the cells partially resistant to freeze/thaw-induced damages, which ultimately results in hemolysis. Biochemical stabilization may be targeted to maintain metabolic components, antioxidant potential, intracellular ionic distribution, membrane fluidity, and integrity of the cytoskeletal structure.
- specific second messenger pathways such as the cyclooxygenase, lipoxygenase, hexose monophosphate and phosphorylation pathways, may be manipulated directly by biochemical reagents or indirectly through regulation of specific messenger molecules, including cyclic-adenosine monophosphate (c-AMP), cyclic-guanine monophosphate (c-GMP), intracellular calcium, inositol triphosphate, and diacylglycerol.
- c-AMP cyclic-adenosine monophosphate
- c-GMP cyclic-guanine monophosphate
- intracellular calcium inositol triphosphate
- diacylglycerol diacylglycerol
- a single reagent or combination of reagents may be added to red blood cell units to target each of the above items.
- reagents can be added to maintain or enhance intracellular concentrations of ATP such as glucose, pyruvate or inorganic phosphate as well as blocking ATP-depleting ATPases such as amiloride mediated inhibition of the Na + /H + exchanger.
- Preventing oxidative damage to the membrane or hemoglobin may be accomplished through the addition of antioxidants such as glutathione, tocopherol, ascorbate and bioflavonoids as well as through the stimulation of the hexose monophosphate pathway by ribose.
- Ionic distribution can be regulated through activation or inhibition of specific ion pumps.
- Calcium may be controlled with nifedipine or verapamil while amiloride will effect sodium regulation as mentioned above. Further potassium and chloride ionic distribution may be maintained through inhibition of the K + /Cl ⁇ co-transporter with bumetamide.
- the cyclooxygenase and lipoxygenase pathways may be regulated through the addition of flurbiprofen, dipyridamole, or aspirin while phosphorylation events can be manipulated through inhibition by kinase inhibitors such as H7 (1-[5-isoquinolinylsulfonyl]-2-methylpiperazine), staurosporin, or chelerythrine or stimulated by diacylglycerol palmitoyl carnitine.
- Membrane stabilization and fluidity is controlled through the addition of pentoxifylline, nicotinamide or amantadine and cytoskeletal structure may be maintained through actin stabilization by the use of Taxol, [2aR-[2a ⁇ ,4 ⁇ ,4a ⁇ ,6 ⁇ ,9 ⁇ ( ⁇ R*, ⁇ S*,11 ⁇ , ⁇ 12 ⁇ ,12a ⁇ ,12b ⁇ ]]- ⁇ -(Benzoylamino)- ⁇ -hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8,13,-13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca [3,4]benz-[1,2-b]oxet-9-yl-ester, or cytochalasins or spectrin stabilization with poly
- cryoprotectants are used to protect the red blood cell unit from damage by ice crystal formation during the freeze/thaw cycle.
- the cryoprotectants may be used individually or as mixtures made up of penetrating and/or non-penetrating compounds.
- potential cryoprotectants include, but are not limited to dimethylsulfoxide, polyvinyl pyrrolidone, dextran, maltodextrins, 2,3-butanediol, hydroxyethyl starch, polyethylene glycol and glucose and other carbohydrates.
- the method includes drawing a volume of packed red blood cells in ADSOL, a currently licensed additive solution sold by Baxter Travenol, using standard blood banking protocols.
- ADSOL is removed by centriftigation, and a volume of preservation solution containing the desired cryoprotectants and any additional biochemical reagents is added.
- the red blood samples containing cryoprotectants are submerged in liquid nitrogen for freezing and immediately transferred to a ⁇ 80° C. freezer for extended storage.
- Biochemical stabilization may be targeted to maintain metabolic components, antioxidant potential, intracellular ionic distribution, membrane fluidity and integrity of cytoskeletal structure.
- specific second messenger pathways such as the cyclooxygenase, lipoxygenase, hexose monophosphate and phosphorylation pathways, may be manipulated directly by biochemical reagents or indirectly through regulation of specific messenger molecules, including c-AMP, c-GMP, intracellular calcium, inositol triphosphate, and diacylglycerol.
- the biochemical reagents are present in a concentration so as to prevent the hemolysis of the red blood cells during the freeze/thaw cycle and even more preferably have concentrations of about 500 ⁇ M nifefipine, about 20 ⁇ M cytochalasin B, about 500 ⁇ M Taxol, about 5 mM pentoxifylline, and about 25 ⁇ g/ml flurbiprofen.
- the biochemical reagents are present in 2.5% DMSO as a carrier agent. All conditions contain 7.5% dextran (Dex; 40,000 MW), 2% polyvinyl pyrrolidone (PVP; 40,000 MW), 5% hydroxyethyl starch, and 5% polyethylene glycol.
- cryoprotectants can work in combination to protect the red blood cells during cryopreservation better than any single cryoprotectant alone.
- the addition of the reagents and the biochemical modulation with the low concentrations of transfusable cryoprotectants works in combination to further protect the red blood cells during cryopreservation.
- An alternative method is to add the isotonic saline or preservative solution containing the biochemical reagents and a volume of Glycerolyte 57 (Fenwall), preferably about 20% glycerol and freeze the bags at ⁇ 80° C.
- the additives used include nicotinamide, nikethamide, nifedipine, pentoxifylline, and flurbiprofen.
- the 20% glycerol with the addition of the biochemical additives reduces the level of hemolysis and meets the criteria for a transfusable blood unit based on the overall hemolysis and residual free hemoglobin levels.
- one embodiment of the present invention is a red blood cell storage composition including a red blood cell composition and a composition of biochemical stabilization reagents.
- the biochemical reagents should be present at a concentration so as to permit decreased hemolysis during the freeze-thaw cycle and increased in vitro functional activity when compared to red blood cells preserved under the same conditions but in the absence of the biochemical reagents.
- a red blood cell composition comprising red blood cells, a composition of red blood cells and biochemical reagents, and a combination of one or more cryoprotective agents.
- Another embodiment is directed to a human red blood cell composition
- a human red blood cell composition comprising human red blood cells, a composition of red blood cells and biochemical reagents.
- Reagents can be added to maintain or enhance intracellular concentrations of ATP such as glucose, pyruvate or inorganic phosphate as well as blocking ATP-depleting ATPases such as amiloride inhibition of the Na + /H + exchanger.
- Preventing oxidative damage to the membrane or hemoglobin may be accomplished through the addition of antioxidants such as glutathione, tocopherol, ascorbate and bioflavonoids as well as through the stimulation of the hexose monophosphate pathway by ribose.
- Ionic distribution can be regulated through activation or inhibition of specific ion pumps.
- Calcium may be controlled with nifedipine or verapamil while amiloride will effect sodium regulation as mentioned above. Further potassium and chloride ionic distribution may be maintained through inhibition of the K + /Cl ⁇ co-transporter with bumetamide.
- the cyclooxygenase and lipoxygenase pathways may be regulated through the addition of flurbiprofen, dipyridamole, or aspirin while phosphorylation events can be manipulated through inhibition by kinase inhibitors such as H7 (1-[5-isoquinolinylsulfonyl]-2-methylpiperazine), staurosporin, or chelerythrine or stimulated by diacylglycerol palmitoyl carnitine.
- Membrane stabilization and fluidity is controlled through the addition of pentoxifylline, nicotinamide or amantadine and cytoskeletal structure may be maintained through actin stabilization by the use of TAXOL or cytochalasins or spectrin stabilization with polyamines.
- Specific cyclic nucleotide regulated second messenger pathways may be activated through the use of adenosine (elevates c-AMP) and sodium nitroprusside or other nitric oxide donors (elevates c-GMP).
- the biochemical reagents are present in a concentration so as to prevent the hemolysis of the red blood cells during the freeze/thaw cycle.
- the biochemical stabilization of this invention is based on the application of specific effectors, which target specific aspects of cellular biochemistry to protect cells against specific modes of damage.
- the method of cryopreservation is such that the stored cells may be directly transfused following thaw, by combining biochemical reagents and low concentrations of transfusable cryoprotectants.
- the biochemical stabilization involves regulation of the metabolic, ionic, cytoskeletal, and membrane component, rendering the treated red blood cells less susceptible to damage induced during freezing and thawing at temperatures between ⁇ 10° C. to ⁇ 193° C.
- specific cellular effectors are nifedipine, cytochalasin B, Taxol, pentoxifylline, flurbiprofen, nikethamide, ribose, and trehalose. These modifiers are added to the packed red blood cells and the preservative solution. Each of the modifiers affects different specific cellular biochemistry.
- nifedipine an inhibitor acting through the calcium cascade controls calcium
- cytochalasin B and Taxol are cytoskeletal modifiers and provide stabilization to the cell through actin stabilization.
- membrane stabilization and fluidity may be controlled through pentoxifylline, a membrane modifier. Ribose is added to prevent oxidative damage to the cell by stimulation of the hexose monophosphate pathway.
- the second messenger effectors have been demonstrated to provide biochemical stabilization to the red blood cells either individually or in combination with others. More, importantly, the addition of these reagents allows biochemical modulation to enhance cryoprotection at lower glycerol concentrations which normally result in nearly 100% of the red blood cells being inadequately protected during the freeze/thaw and washing cycles.
- the chemicals which have shown utility as effectors of the second messenger pathways it must be understood that the actual chemicals mentioned together with functionally equivalent materials are intended to be within the scope of this invention. Chemicals that are known to applicants to have known or demonstrated utility as modifiers have been specifically set forth in the instant application. However, it is intended that the scope of the application be extended to other functionally effective chemicals, both existing chemicals and chemicals yet to be discovered.
- Certain chemicals which are thought to be functionally equivalent materials for the modifier acting through the second messenger pathway are those selected from cyclic-adenosine monophosphate, c-(AMP), cyclic-guanine monophosphate, c-(GMP), intracellular calcium, inositol triphosphate, and diacylglycerol.
- Functionally equivalent modifiers acting through the cyclic nucleotide regulated second messenger pathway are those selected from adenosine, sodium nitroprusside, and other nitric oxide donors.
- Materials thought to be functionally equivalent to the modifier of intracellular concentrations of ATP are those selected from glucose, pyruvate, and inorganic phosphate, as well as ATP-depleting ATPases such as amiloride.
- Preventing oxidative damage to the membrane or hemoglobin may be accomplished through the addition of functionally equivalent antioxidants such as glutathione, tocopherol, ascorbate and bioflavonoids as well as through the stimulation of the hexose monophosphate pathway by ribose.
- Ionic distribution can be regulated through activation or inhibition of specific ion pumps.
- Functionally equivalent modifiers of calcium may be selected from nifedipine or verapamil while amiloride will effect sodium regulation as mentioned above. Further potassium and chloride ionic distribution may be maintained through inhibition of the K + /Cl ⁇ co-transporter with bumetamide.
- cyclooxygenase and lipoxygenase pathways may be regulated through the addition of functionally equivalent modifiers of flurbiprofen, dipyridamole, or aspirin while phosphorylation events can be manipulated through inhibition by kinase inhibitors such as H7 (1-[5-isoquinolinylsulfonyl]-2-methylpiperazine), staurosporin, or chelerythrine or stimulated by diacylglycerol palmitoyl carnitine, which are also functionally equivalent reagents.
- kinase inhibitors such as H7 (1-[5-isoquinolinylsulfonyl]-2-methylpiperazine
- staurosporin staurosporin
- chelerythrine or stimulated by diacylglycerol palmitoyl carnitine
- Reagents which are functionally equivalent regulators of membrane stabilization and fluidity are pentoxifylline, nicotinamide or amantadine, while for the regulation of cytoskeletal structure through actin stabilization, the reagents are TAXOL or cytochalasins and for spectrin stabilization, polyamines.
- Specific cyclic nucleotide regulated second messenger pathways may be activated through the use of functionally equivalent adenosine (elevates c-AMP) and sodium nitroprusside or other nitric oxide donors (elevates c-GMP).
- the post-thaw life of the red blood cells after cryopreservation may be successfully extended by storing the cells at ⁇ 80° C. with the biochemical reagents of this invention.
- red blood cells were stored for 3-7 days in a ⁇ 80° C. freezer and thawed at 37° C.
- a packed red blood cell unit in ADSOL was obtained using standard blood banking protocols.
- the ADSOL was removed by centrifugation and a volume of preservation solution containing the desired cryoprotectants and biochemical reagents was added.
- the final concentrations of cryoprotectant used were 7.5% dextran, 2% polyvinyl pyrrolidone, 5% hydroxyethyl starch, and 2.5% dimethyl sulfoxide as a biochemical reagent carrier.
- Reagents used included 500 ⁇ M nifedipine, 20 ⁇ M cytochalasin B, 500 ⁇ M Taxol, 5 mM pentoxifylline and 25 ⁇ g/ml flurbiprofen.
- cryoprotective agent such as dimethlyl sulfoxide (DMSO).
- Cryoprotective agents such as DMSO are polar molecules which penetrates the cell membrane and serves to preserve cell viability during the cryopreservation process.
- other cryoprotective agents used in this invention include polyvinyl pyrrolidone, dextran maltodextrins, 2,3-butanadiol, hydroxyethyl starch, polyethylene glycol, glucose, and combinations thereof.
- cryoprotectants may be used individually or as mixtures made up of penetrating and/or non-penetrating compounds in transfusable concentrations to protect the red blood cells from damage by ice crystal formation during the freeze/thaw cycle.
- cryoprotectants allow increased protection from hemolysis than a single cryoprotective agent: 7.5% dextran, 11.19% hemolysis; 2% polyvinyl pyrrolidone, 47.39% hemolysis; 5% hydroxyethyl starch, 43.17% hemolysis; 7.5% dextran and 2% polyvinyl pyrrolidone, 6.42% hemolysis; 7.5% dextran and 5% hydroxyethyl starch, 8.56% hemolysis; 2% polyvinyl pyrrolidone and 5% hydoxyethyl starch, 23.46% is hemolysis, and finally 7.5% dextran, 2% polyvinyl pyrrolidone, and 5% hydroxethyl starch, 4.44% hemolysis.
- a red blood cell storage composition of the present invention includes a storage composition, a composition of red blood cells, and a composition of biochemical reagents, the reagents present in a concentration so as to prevent the hemolysis of the red blood cells during the freeze/thaw cycle and in a concentration to increase the in vitro functional activity when compared to red blood cells preserved under the same conditions but in the absence of the biochemical reagents.
- the “storage composition,” is intended to mean a pharmacologically inert fluid into which the red blood cells may be suspended and which does not adversely affect the preservation abilities of the compositions disclosed herein, for example physiological saline.
- Biochemical stabilization may be targeted to maintain metabolic components, antioxidant potential, intracellular ionic distribution, membrane fluidity and integrity of cytoskeletal structure. Additionally, specific second messenger pathways, such as the cyclooxygenase, lipoxygenase, hexose monophosphate and phosphorylation pathways, may be manipulated directly by biochemical reagents or indirectly through regulation of specific messenger molecules, including cyclic-adenosine monophosphate, (c-AMP), cyclic-guanine monophosphate, (c-GMP), intracellular calcium, inositol triphosphate, and diacylglycerol.
- c-AMP cyclic-adenosine monophosphate
- c-GMP cyclic-guanine monophosphate
- intracellular calcium inositol triphosphate
- diacylglycerol diacylglycerol
- the modifiers acting through the second messenger pathway is selected from cyclic-adenosine monophosphate, (c-AMP), cyclic guanine monophosphate, (c-GMP), intracelluar calcium, inositol triphosphate, and diacylglycerol.
- Reagents can be added to maintain or enhance intracellular concentrations of ATP such as glucose, pyruvate or inorganic phosphate as well as blocking ATP-depleting ATPases such as amiloride inhibition of the Na + /H + exchanger.
- Preventing oxidative damage to the membrane or hemoglobin may be accomplished through the addition of antioxidants such as glutathione, tocopherol, ascorbate and bioflavonoids as well as through the stimulation of the hexose monophosphate pathway by ribose.
- Ionic distribution can be regulated through activation or inhibition of specific ion pumps. Calcium may be controlled with nifedipine or verapamil while amiloride will effect sodium regulation as mentioned above. Further potassium and chloride ionic distribution may be maintained through inhibition of the K + /Cl ⁇ co-transporter with bumetamide.
- cyclooxygenase and lipoxygenase pathways may be regulated through the addition of flurbiprofen, dipyridamole, or aspirin while phosphorylation events can be manipulated through inhibition by kinase inhibitors such as H7 (1-[5-isoquinolinylsulfonyl]-2-methylpiperazine), staurosporin, or chelerythrine or stimulated by diacylglycerol palmitoyl carnitine.
- kinase inhibitors such as H7 (1-[5-isoquinolinylsulfonyl]-2-methylpiperazine
- staurosporin staurosporin
- chelerythrine or stimulated by diacylglycerol palmitoyl carnitine.
- Membrane stabilization and fluidity is controlled through the addition of pentoxifylline, nicotinamide or amantadine and cytoskeletal structure may be maintained through actin stabilization by the use of TAXOL or cytochalasins or spectrin stabilization with polyamines.
- Specific cyclic nucleotide regulated second messenger pathways may be activated through the use of adenosine (elevates c-AMP) and sodium nitroprusside or other nitric oxide donors (elevates c-GMP).
- the biochemical reagents are: nifedipine in a concentration of about 500 ⁇ M, cytochalasin B in a concentration of about 20 ⁇ M, Taxol in a concentration of about 500 ⁇ M, pentoxifylline in a concentration of about 5 mM, and flurbiprofen in a concentration of about 25 ⁇ g/ml.
- the blood cell storage composition of the present embodiment may further include a cryoprotective agent, the cryoprotective agent being selected from dimethyl sulfoxide, polyvinyl pyrrolidone, dextran maltodextrins, 2,3-butandiol, hydroxyethyl starch, polyethylene glycol, glucose, and combinations thereof.
- the cryoprotective agents are: dextran in a concentration of about 7.5%; polyvinyl pyrrolidone in a concentration of about 2%; dimethyl sulfoxide in a concentration of about 2.5%; hydroxyethyl starch in a concentration of about 5%, and polyethylene glycol in a concentration of about 5%.
- the prolonged storage of the red blood cells should be carried out at a temperature below the red cells' normal physiological temperature. In one embodiment, the temperature is from about —10° C. to about ⁇ 193° C. In another embodiment the temperature below the red blood cells' normal physiological temperature is about ⁇ 80° C.
- the following example demonstrates the damage induced during the freeze/thaw cycle when the glycerol concentration is decreased.
- a significant percentage of the hemolytic damage is shown to be reversed by the addition of a preservative solution containing adenine, glutamine, sodium chloride, mannitol, and dextrose, with the essential additive being dextrose, and final concentrations of 5 mM pentoxifylline and 25 ⁇ g/ml flurbiprofen in DMSO as a carrier.
- the level of thaw hemolysis was determined as the ratio of free hemoglobin to total hemoglobin. The levels of thaw hemolysis are shown below in TABLE 1. TABLE 1 LEVELS OF THAW HEMOLYSIS % Hemolysis 40% Glycerol 1.91 30% Glycerol 3.53 20% Glycerol 35.29 20% + Additives 14.87
- the following example further demonstrates the damage induced during the freeze/thaw cycle when the glycerol concentration is decreased, after red blood cells are frozen and stored at ⁇ 80° C.
- Fifty ml of packed red blood cells were added to a PVC freezing bag. Isotonic saline or preservative solution containing the additional biochemical reagents of interest was mixed with the red blood cells.
- the samples were treated as follows prior to freezing at ⁇ 80° C.:
- a volume of Glycerolyte 57 (Fenwall) was added slowly until the final concentration of glycerol was achieved. The total volume of all additions was 50 ml, making the final volume of the red blood cell unit 100 ml.
- the PVC bags were frozen at ⁇ 80° C. for 2-7 days and thawed by submersion in a 37° C. water bath for 10 minutes. The level of thaw hemolysis was determined as the ratio of free hemoglobin to total hemoglobin. Additionally, the glycerol was removed from the thawed red blood cell units by serial dilution with saline similar to blood bank protocols. The overall hemolysis and the final residual free hemoglobin levels were also determined.
- TABLE 2 compares 40% glycerol to 20% glycerol and 20% glycerol with the indicated additives.
- the additives used included nicotinamide, nikethamide, nifedipine, pentoxifylline, and flurbiprofen.
- the results of 20% glycerol with all additives meet the criteria for a transfusable blood unit based on the overall hemolysis and residual free hemoglobin levels. These results confirm the loss of red blood cell protection at reduced glycerol concentrations and the ability of biochemical reagents to provide cryoprotection at glycerol concentrations which alone are unable to completely protect red blood cell during cryopreservation.
- the following experiment demonstrates the ability of biochemical addition to provide protection against damage during cryopreservation.
- the model used is a reduced glycerol cryopreservation system. 10% (w/v) glycerol is added to the unit prior to freezing at ⁇ 80° C. A significant level of hemolysis occurs so that protection by the added reagent may be distinguished.
- a single unit of packed red blood cells in ADSOL was obtained using standard blood banking protocols.
- the ADSOL was removed by centrifugation and a volume of preservation solution was added until the resulting hematocrit was about 50%.
- 50 ml of red cells was placed into each of 3 PVC freezing bags having a maximum volume of 150 ml.
- An equal volume (50 ml) was added to each of the bags composed of the above preservation solution and the experimental conditions.
- the final composition of the first bag was 10% (w/v) glycerol.
- the second contained 10% (w/v) glycerol and 2.5% DMSO and 500 ⁇ M nifedipine.
- the bags were frozen at ⁇ 80° C.
- This example further confirms the ability of biochemical modulation to enhance cryoprotection at glycerol concentrations which normally result in nearly 100% of the red blood cells being inadequately protected during the freeze/thaw cycles.
- This example demonstrates the ability of biochemical stabilization to enhance red blood cell cryopreservation in conjunction with a glycerol based cryoprotectant.
- An aliquot of blood was transferred to a PVC storage bag, to which any experimental agents were added. Glycerol was then added until the desired final glycerol was achieved. This unit was frozen at ⁇ 80° C., stored and thawed in a 37° C. water bath for 10 minutes. The glycerol was removed by serial dilution and centrifugation with 12%, 1.6% and 0.9% saline until the residual free hemoglobin is less than 2% of the total hemoglobin content.
- TABLE 4 show results following the desired procedure. The values indicate the percent hemolysis in the thawed sample, the overall amount of hemolysis following the wash and the is percent of residual free hemoglobin in the final sample. Hemolysis is calculated as the ratio of free hemoglobin to the total hemoglobin content in the sample.
- the following example demonstrates that biochemical stabilization using non-cryoprotective reagents reduces the level of hemolysis when using alternative polymeric reagents as the primary cryoprotectants, when red blood are plunge frozen and subsequently stored at ⁇ 80° C.
- a volume of packed red blood cell was mixed with an equal volume of preservation solution containing the desired cryoprotectants and any additional biochemical reagents.
- the final concentrations of cryoprotectants used were 7.5% dextran (Dex; 40,000 MW) and 2% polyvinyl pyrrolidone (PVP; 40,000 MW).
- the red blood cell samples containing cryoprotectants were submerged in liquid nitrogen for 3 minutes to freeze and immediately transferred to a ⁇ 80° C. freezer for extended storage.
- the samples were thawed at 37° C. in a water bath, and the level of thaw hemolysis was determined as the ratio of free hemoglobin to total hemoglobin. Additionally, the glycerol was removed from the thawed red blood cell units by serial dilution with saline similar to blood bank protocols. The overall hemolysis and the final residual free hemoglobin were also determined.
- Reagents used include 500 ⁇ M nifedipine, 20 ⁇ M cytochalasin B, 500 ⁇ M Taxol, 5 mM pentoxifylline, and 25 ⁇ g/ml flurbiprofen in several combinations.
- the following example describes an experiment to measure the biochemical stabilization and the post-thaw hemolytic lesion upon dilution, analogous to transfusion, after red blood cell are plunge frozen and stored at ⁇ 80° C. This type of storage lesion is not commonly addressed but is observed with most non-glycerol based cryoprotective solutions.
- a volume of packed red is blood cell was mixed with an equal volume of preservation solution containing the desired cryoprotectants and any additional biochemical reagents.
- cryoprotective additive solution containing 7.5% dextran (Dex; 40.000 MW) 2% polyvinyl pyrrolidone (PVP; 40,000 MW), 5% hydroxyethyl starch (HES), and 5% polyethylene glycol (PEG), the red blood cell samples containing cryoprotectants were submerged in liquid nitrogen for 3 minutes to freeze and immediately transferred to a ⁇ 80° C. freezer for extended storage. Following storage the thaw samples were split into two aliquots. The first aliquot was analyzed immediately, and the remaining aliquot was incubated at 4° C. for 3 hours prior to analysis. The analyzed endpoints included hemolysis in the thawed sample and the additional hemolysis which occurs upon 1:1 dilution with one of 2 different diluent solution, PBS or isotype plasma.
- CPA cryoprotective additive solution
- a single packed red blood cell unit containing ADSOL was obtained and prepared using standard blood banking protocols.
- the ADSOL was removed by centrifugation and a volume of preservation solution was added.
- a volume of the resulting red blood cell unit was mixed with an equal volume of preservation solution containing the desired cryoprotectant(s).
- the final concentrations of cryoprotectants used were 7.5% dextran (Dex; 40,000 MW), 2% polyvinyl pyrrolidone (PVP; 40,000 MW) and 5% hydroxyethyl starch (HES).
- the red blood cell samples containing cryoprotectants were submerged in liquid nitrogen for three minutes to freeze and immediately transferred to a ⁇ 80° C. freezer for extended storage.
- one illustrative embodiment of the present invention includes a red blood cell storage composition which includes a composition of red blood cells and biochemistry altering reagents, the biochemistry altering reagents being present at a concentration so as to reduce the percent hemolysis of the red blood cells during the freeze-thaw cycle below that of the percent hemolysis of the red blood cells in the absence the biochemistry altering reagents.
- the reagents of the present illustrative embodiment are selected from: modifiers of glycolytic/metabolic components, modifiers of antioxidant potential, effectors of intracellular ionic distribution, modifiers of membrane fluidity, modifiers of cytoskeletal structure, effectors of the cyclooxygenase second messenger pathway, effectors of the lipoxygenase second messenger pathway, effectors of the hexose monophosphate second messenger pathway, effectors of the phosphorylation second messenger pathway, modifiers of the cyclic nucleotide regulated second messenger pathway, and combinations thereof.
- the reagents of the present illustrative embodiment are selected such that: the modifier of glycolytic/metabolic components is selected from glucose, pyruvate, inorganic phosphate, products of the glycolytic pathway such as adenosine triphosphate, nicotinamide adenine dinucleotide, and inhibitors of glycolysis such as iodacetic acid, rotenone, and carbonyl cyanide p-(trifluoromethoxyl)-phenyl hydrazine; the modifier of antioxidant potential is selected from glutathione, tocopherol, ascorbate, ⁇ -tocopherol, mannitol, bioflavonoids, and derivatives of bioflavonoids including rutin, quercetin, and curcumin; the effector of intracellular ionic is distribution acting through the second messenger pathway is selected from nifedipine, nisoldipine, benzamil, glybenclamidediltiazem
- the illustrative composition may also be formulated such that the biochemistry altering reagents are combined with one or more cryoprotective agent.
- the cryoprotective agent may be a permanent cryoprotectant, preferably the permanent cryoprotectant may be selected from glycerol, dimethyl sulfoxide, 2,3-butandiol, 1,2-propandiol, 1,3-propandiol, polypropylene glycol, N,N-dimentylacetamide, and 1,3,5-trimethyl pentanetriol and combinations thereof.
- the composition may be formulated such that the cryoprotective agent is a non-permanent cryoprotectant, which preferably may be selected from hydoxyethyl starch, dextran, polyvinyl pyrrolidone, polyethylene, polyethylene glycol and combinations thereof.
- a combination of one or more permanent cryoprotectants and one or more non-permanent cryoprotectants may also be utilized in the formulation of the present illustrative embodiment.
- the non-permanent cryoprotectant it is preferred that the non-permanent cryoprotectant have a molecular weight of at least about 5,000 MW.
- a human red blood cell composition including: red blood cells; a storage composition; and a composition of reagents, wherein the composition of reagents is selected from: modifiers of metabolic components, modifiers of antioxidant potential, effectors of intracellular ionic distribution, modifiers of membrane fluidity, modifiers of cytoskeletal structure, effectors of the cyclooxygenase second messenger pathway, effectors of the lipoxygenase second messenger pathway, effectors of the hexose monophosphate second messenger pathway, effectors of the phosphorylation second messenger pathway, modifiers of the cyclic nucletide regulated second messenger pathway, and combinations thereof.
- the composition of reagents is selected from: modifiers of metabolic components, modifiers of antioxidant potential, effectors of intracellular ionic distribution, modifiers of membrane fluidity, modifiers of cytoskeletal structure, effectors of the cyclooxygenase second messenger pathway, effectors of the lipoxygenase second messenger pathway, effectors of the hex
- the modifier of glycolytic/metabolic components is selected from glucose, pyruvate, inorganic phosphate, products of the glycolytic pathway such as adenosine triphosphate, nicotinamide adenine dinucleotide, and inhibitors of glycolysis such as iodacetic acid, rotenone, and carbonyl cyanide p-(trifluoromethoxyl)-phenyl hydrazine;
- the modifier of antioxidant potential is selected from glutathione, tocopherol, ascorbate, ⁇ -tocopherol, mannitol, bioflavonoids, and derivatives of bioflavonoids including rutin, quercetin, and curcumin;
- the effector of intracellular ionic distribution acting through the second messenger pathway is selected from nifedipine, nisoldipine, benzamil, glybenclamidediltiazem, clotrimizole,
- the illustrative composition may be formulated such that the composition of reagents are combined with one or more cryoprotective agents.
- the cryoprotective agent is a permanent cryoprotectant selected from glycerol, dimethyl sulfoxide, 2,3-butandiol, 1,2-propandiol. 1,3-propandiol, polypropylene glycol, N,N-dimentylacetamide, 1,3,5-trimethyl pentanetriol and combinations thereof.
- the cryoprotective agent is a non-permanent cryoprotectant selected from hydoxyethyl starch, dextran, polyvinyl pyrrolidone, polyethylene, polyethylene glycol and combinations thereof.
- the cryoprotective solution is a combination of one or more permanent cryoprotectants and one or more non-permanent cryoprotectants.
- a non-permanent cryoprotectant is utilized in the formulation, it is preferred that the non-permanent cryoprotectant have a molecular weight of at least 5000 MW.
- the illustrative embodiment should be formulated such that the biochemical reagents are present in a concentration so that upon in vitro preservation of the red blood cells at a temperature below the red blood cells normal physiological temperature for a period of about 2-7 days, the red blood cells exhibit decreased hemolysis during a freeze-thaw cycle and increased in vitro functional activity when compared to red blood cells preserved under the same conditions but in the absence of the biochemical reagents.
- the nifedipine has a concentration of about 500 ⁇ M
- the cytochalasin B has a concentration of about 20 ⁇ M
- the Taxol has a concentration of about 500 ⁇ M
- the pentoxifylline has a concentration of about 5 mM
- the flurbiprofen has a concentration of about 25 ⁇ g/ml
- the nikethamide has a concentration of about (1% v/v)
- the ribose has a concentration of about 0.50 mM
- the trehalose has a concentration of about 50 mM.
- the present invention includes a method for storing human red blood cells including: (a) isolating red blood cells from fresh human blood; (b) forming a red blood cell composition; and (c) storing the resulting red blood cell composition at a temperature below normal human physiological temperature effective to preserve the blood cells for a selected period of time.
- the red blood cell composition should be formulated so as to include: red blood cells; a storage composition; and a composition of reagents.
- composition of reagents should be selected from: modifiers of metabolic components, modifiers of antioxidant potential, effectors of intracellular ionic distribution, modifiers of membrane fluidity, modifiers of cytoskeletal structure, effectors of the cyclooxygenase second messenger pathway, effectors of the lipoxygenase second messenger pathway, effectors of the hexose monophosphate second messenger pathway, effectors of the phosphorylation second messenger pathway, modifiers of the cyclic nucleotide regulated messenger pathway, and combinations thereof.
- the temperature below normal physiological temperature effective to preserve the red blood cells for selected period of time is preferably about ⁇ 10° C. to ⁇ 193° C., and more preferably is about ⁇ 80° C.
- compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and methods and in the steps or in the sequence of steps of the method described herein without departing from the concept and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the concept and scope of the invention as defined by the appended claim.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Dentistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/334,950 US20060127375A1 (en) | 1998-05-26 | 2006-01-18 | Cryopreservation of human red blood cells |
US13/368,460 US8895236B2 (en) | 1998-05-26 | 2012-02-08 | Composition for cryopreservation comprising nicotinamide, glycerol and red blood cells |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8683698P | 1998-05-26 | 1998-05-26 | |
PCT/US1999/011674 WO1999060849A1 (en) | 1998-05-26 | 1999-05-26 | Cryopreservation of human red blood cells |
US62384600A | 2000-09-07 | 2000-09-07 | |
US11/334,950 US20060127375A1 (en) | 1998-05-26 | 2006-01-18 | Cryopreservation of human red blood cells |
Related Parent Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/011674 Continuation WO1999060849A1 (en) | 1998-05-26 | 1999-05-26 | Cryopreservation of human red blood cells |
US09623846 Continuation | 1999-05-26 | ||
US62384600A Continuation | 1998-05-26 | 2000-09-07 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/368,460 Division US8895236B2 (en) | 1998-05-26 | 2012-02-08 | Composition for cryopreservation comprising nicotinamide, glycerol and red blood cells |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060127375A1 true US20060127375A1 (en) | 2006-06-15 |
Family
ID=22201233
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/334,950 Abandoned US20060127375A1 (en) | 1998-05-26 | 2006-01-18 | Cryopreservation of human red blood cells |
US13/368,460 Expired - Fee Related US8895236B2 (en) | 1998-05-26 | 2012-02-08 | Composition for cryopreservation comprising nicotinamide, glycerol and red blood cells |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/368,460 Expired - Fee Related US8895236B2 (en) | 1998-05-26 | 2012-02-08 | Composition for cryopreservation comprising nicotinamide, glycerol and red blood cells |
Country Status (9)
Country | Link |
---|---|
US (2) | US20060127375A1 (de) |
EP (1) | EP1082006B1 (de) |
JP (1) | JP2002516254A (de) |
AT (1) | ATE316757T1 (de) |
AU (1) | AU758703C (de) |
CA (1) | CA2332986C (de) |
DE (1) | DE69929691T2 (de) |
ES (1) | ES2257050T3 (de) |
WO (1) | WO1999060849A1 (de) |
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090035289A1 (en) * | 2005-09-26 | 2009-02-05 | Lifecell Corporation | Dry platelet composition |
US20090239208A1 (en) * | 2008-03-21 | 2009-09-24 | Veronique Mayaudon | Red Blood Cell Storage Medium For Extended Storage |
US20090306790A1 (en) * | 2008-06-06 | 2009-12-10 | Wendell Sun | Elastase Treatment of Tissue Matrices |
US20100040687A1 (en) * | 2008-08-14 | 2010-02-18 | Kci Licensing, Inc. | Tissue Scaffolds |
US20100255524A1 (en) * | 2007-05-31 | 2010-10-07 | Qiagen Gmbh | Method for stabilising a biological sample |
US20100272782A1 (en) * | 2007-07-10 | 2010-10-28 | Owens Rick T | Acellular tissue matrix compositions for tissue repair |
US20110117647A1 (en) * | 2008-03-21 | 2011-05-19 | Fenwal, Inc. | Red Blood Cell Storage Medium For Extended Storage |
US20110238186A1 (en) * | 2010-03-25 | 2011-09-29 | Lifecell Corporation | Preparation of regenerative tissue scaffolds |
US8333803B2 (en) | 2008-11-21 | 2012-12-18 | Lifecell Corporation | Reinforced biologic material |
US8735054B1 (en) | 2008-01-04 | 2014-05-27 | Lifecell Corporation | Acellular tissue matrix preservation solution |
US9150318B1 (en) | 2009-01-02 | 2015-10-06 | Lifecell Corporation | Method for sterilizing an acellular tissue matrix |
US9206442B2 (en) | 2011-04-28 | 2015-12-08 | Lifecell Corporation | Method for enzymatic treatment of tissue products |
US9238793B2 (en) | 2011-04-28 | 2016-01-19 | Lifecell Corporation | Method for enzymatic treatment of tissue products |
US9370536B2 (en) | 2012-09-26 | 2016-06-21 | Lifecell Corporation | Processed adipose tissue |
US9409128B2 (en) | 2009-10-23 | 2016-08-09 | Fenwal, Inc. | Methods for storing red blood cell products |
WO2017013664A1 (en) * | 2015-07-22 | 2017-01-26 | Ramot At Tel-Aviv University Ltd. | Article of manufacture and methods for increasing survival of red blood cells |
US9592254B2 (en) | 2013-02-06 | 2017-03-14 | Lifecell Corporation | Methods for localized modification of tissue products |
US9592278B2 (en) | 2012-03-08 | 2017-03-14 | Lifecell Corporation | Enzyme-activated collagen and tissue matrices |
US10207025B2 (en) | 2011-04-28 | 2019-02-19 | Lifecell Corporation | Method for enzymatic treatment of tissue products |
US10307510B2 (en) | 2013-11-04 | 2019-06-04 | Lifecell Corporation | Methods of removing alpha-galactose |
US10363343B2 (en) | 2012-07-05 | 2019-07-30 | Lifecell Corporation | Tissue-based drain manifolds |
US10413634B2 (en) | 2017-01-30 | 2019-09-17 | Lifecell Corporation | Transglutaminase treated products |
US10758336B2 (en) | 2012-07-06 | 2020-09-01 | Lifecell Corporation | Decellularized muscle matrix |
US10792394B2 (en) | 2016-06-03 | 2020-10-06 | Lifecell Corporation | Methods for localized modification of tissue products |
US10821205B2 (en) | 2017-10-18 | 2020-11-03 | Lifecell Corporation | Adipose tissue products and methods of production |
US10850008B2 (en) | 2015-12-11 | 2020-12-01 | Lifecell Corporation | Methods and systems for stiffening of tissue for improved processing |
US10940184B2 (en) | 2017-01-30 | 2021-03-09 | Lifecell Corporation | Tissue matrix materials and enzymatic adhesives |
WO2021108806A1 (en) * | 2019-11-29 | 2021-06-03 | Rutgers, The State University Of New Jersey | Compositions, kits and methods for storage of blood products and methods of use thereof |
US11045583B2 (en) | 2016-12-22 | 2021-06-29 | Lifecell Corporation | Devices and methods for tissue cryomilling |
US11090338B2 (en) | 2012-07-13 | 2021-08-17 | Lifecell Corporation | Methods for improved treatment of adipose tissue |
US11110201B2 (en) | 2017-01-30 | 2021-09-07 | Lifecell Corporation | Devices including muscle matrix and methods of production and use |
US11123375B2 (en) | 2017-10-18 | 2021-09-21 | Lifecell Corporation | Methods of treating tissue voids following removal of implantable infusion ports using adipose tissue products |
CN113710794A (zh) * | 2019-04-19 | 2021-11-26 | 富士胶片和光纯药株式会社 | 细胞外囊泡的保存稳定化剂及保存稳定化方法 |
US11246994B2 (en) | 2017-10-19 | 2022-02-15 | Lifecell Corporation | Methods for introduction of flowable acellular tissue matrix products into a hand |
US11633521B2 (en) | 2019-05-30 | 2023-04-25 | Lifecell Corporation | Biologic breast implant |
US11826488B2 (en) | 2017-10-19 | 2023-11-28 | Lifecell Corporation | Flowable acellular tissue matrix products and methods of production |
US11957814B2 (en) | 2011-05-31 | 2024-04-16 | Lifecell Corporation | Adipose tissue matrices |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE316757T1 (de) | 1998-05-26 | 2006-02-15 | Lifecell Corp | Cryokonservierung menschlicher roter blutzellen |
US6869757B2 (en) * | 2000-07-31 | 2005-03-22 | 21St Century Medicine, Inc. | Advantageous carrier solution for vitrifiable concentrations of cryoprotectants, and compatible cryoprotectant mixtures |
JP2002226368A (ja) * | 2001-02-02 | 2002-08-14 | Fuji Chem Ind Co Ltd | 赤血球の酸化的損傷抑制剤 |
AU2003302898A1 (en) | 2002-12-11 | 2004-06-30 | Cryolife, Inc. | Radical retardant cryopreservation solutions |
US7935478B2 (en) | 2004-02-02 | 2011-05-03 | Core Dynamics Limited | Biological material and methods and solutions for preservation thereof |
EP1711214A1 (de) | 2004-02-02 | 2006-10-18 | Interface Multigrad Technology (IMT) Ltd. | Vorrichtung zum gerichteten kühlen von biomasse |
RU2418633C2 (ru) | 2004-04-08 | 2011-05-20 | Байоматрика, Инк. | Объединение процессов хранения образцов и управление образцами в медико-биологических науках |
ATE460947T1 (de) | 2004-06-07 | 2010-04-15 | Core Dynamics Ltd | Verfahren zur sterilisation von biologischen präparaten |
US8037696B2 (en) | 2004-08-12 | 2011-10-18 | Core Dynamics Limited | Method and apparatus for freezing or thawing of a biological material |
US8198085B2 (en) | 2005-08-03 | 2012-06-12 | Core Dynamics Limited | Somatic cells for use in cell therapy |
CN1954883B (zh) * | 2005-10-28 | 2011-06-15 | 陕西北美基因股份有限公司 | 一种稳定血红蛋白氧载体样品的方法 |
US7759393B2 (en) | 2006-02-10 | 2010-07-20 | Dupont Tate & Lyle Bio Products Company, Llc | Bio-derived 1,3-propanediol and its conjugate esters as natural and non irritating solvents for biomass-derived extracts, fragrance concentrates, and oils |
JP4714654B2 (ja) * | 2006-09-05 | 2011-06-29 | 全国農業協同組合連合会 | 精液希釈液及び希釈精液の保存方法 |
EP1908346A1 (de) * | 2006-09-27 | 2008-04-09 | Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe | Verfahren zur Herstellung von tiefgefrorenem Blut oder tiefgefrorenem Blutzellen für biologische Untersuchungen |
US20100021879A1 (en) * | 2007-01-19 | 2010-01-28 | The Regents Of The University Of Michigan | Compositions and methods for preserving red blood cells |
CN101971796B (zh) * | 2010-05-26 | 2013-04-17 | 赛业(广州)生物科技有限公司 | 无蛋白非程序细胞冻存液 |
EP2598660B1 (de) | 2010-07-26 | 2017-03-15 | Biomatrica, INC. | Zusammensetzungen zur stabilisierung von dna, rna und proteinen in blut- und anderen biologischen proben während des transports und der lagerung bei umgebungstemperaturen |
EP2598661B1 (de) | 2010-07-26 | 2017-09-27 | Biomatrica, INC. | Zusammensetzungen zur stabilisierung von dna, rna und proteinen in speichel- und anderen biologischen proben während des transports und der lagerung bei umgebungstemperaturen |
FR2964981A1 (fr) * | 2010-09-16 | 2012-03-23 | Inst Europ Expertise In Physiology | Procede de traitement de cellules en vue de leur cryogenisation et procede de cryopreservation de cellules mettant en oeuvre un tel procede. |
DE102010053461A1 (de) | 2010-12-03 | 2012-06-06 | Eberhard Lampeter | Verfahren und Vorrichtung zum Kryokonservieren von biologischem Material |
JP6249415B2 (ja) * | 2012-09-03 | 2017-12-20 | 学校法人北里研究所 | 新規光線過敏症抑制剤トレハンジェリン物質及びその製造法 |
US9725703B2 (en) | 2012-12-20 | 2017-08-08 | Biomatrica, Inc. | Formulations and methods for stabilizing PCR reagents |
JP6412696B2 (ja) * | 2014-02-10 | 2018-10-24 | テルモ株式会社 | 血清調製方法および器具 |
WO2015191632A1 (en) | 2014-06-10 | 2015-12-17 | Biomatrica, Inc. | Stabilization of thrombocytes at ambient temperatures |
CN104304236B (zh) * | 2014-09-30 | 2016-09-14 | 湖州师范学院 | 翘嘴红鲌精液冷冻保存液 |
CN104823967B (zh) * | 2015-05-29 | 2017-06-23 | 广州赛莱拉干细胞科技股份有限公司 | 组合物及其应用、红细胞冻存制剂及其制备方法 |
CN113588501A (zh) | 2015-12-08 | 2021-11-02 | 生物马特里卡公司 | 降低红细胞沉降速率 |
WO2019152837A1 (en) * | 2018-02-02 | 2019-08-08 | The General Hospital Corporation | Methods of supercooling aqueous samples |
US20210219542A1 (en) * | 2018-05-15 | 2021-07-22 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for storage of red blood cells |
EP3861980A1 (de) | 2020-02-06 | 2021-08-11 | Mehrdad Ghashghaeinia | Wirkstoff aus einer zusammensetzung mit erythrozyten |
WO2023122672A1 (en) * | 2021-12-23 | 2023-06-29 | Rubhu Biologics, Inc. | Cryopreservation compositions and methods using red blood cells |
Citations (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4004975A (en) * | 1975-12-30 | 1977-01-25 | The United States Of America As Represented By The Secretary Of The Navy | Method of isolating and cryopreserving human white cells from whole blood |
US4018911A (en) * | 1975-11-10 | 1977-04-19 | The United States Of America As Represented By The Secretary Of The Navy | Method for large volume freezing and thawing of packed erythrocytes |
US4054488A (en) * | 1975-08-14 | 1977-10-18 | Marbach Edward P | Preservation of glucose in blood samples |
US4327799A (en) * | 1979-06-18 | 1982-05-04 | Helmholtz-Institut Fur Biomedizinische Technik | Process and apparatus for freezing living cells |
US4531373A (en) * | 1984-10-24 | 1985-07-30 | The Regents Of The University Of California | Directional solidification for the controlled freezing of biomaterials |
US4774088A (en) * | 1986-01-08 | 1988-09-27 | The United States Of America As Represented By The Deptment Of Health And Human Services | Method and additives for improving the quality and shelf life of stored blood |
US4812310A (en) * | 1986-08-29 | 1989-03-14 | Toru Sato | Preserving solution for blood or packed blood cells and method for preserving blood or packed blood cells by using the same |
US5043261A (en) * | 1989-04-10 | 1991-08-27 | Cryopharm Corporation | Lyophilized and reconstituted red blood cell and hemosome compositions |
US5118512A (en) * | 1990-01-23 | 1992-06-02 | Osteotech, Inc. (A Delaware Corp.) | Process for cryopreserving biological materials and materials prepared thereby |
US5153004A (en) * | 1989-06-02 | 1992-10-06 | Cryopharm Corporation | Freezing and thawing of erythrocytes |
US5242792A (en) * | 1991-02-25 | 1993-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Method for the preservation of red blood cells by lyophilization using glycerol or inositol with disaccharides |
US5309723A (en) * | 1989-02-08 | 1994-05-10 | The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland | Method of freezing red blood cells |
US5364756A (en) * | 1990-09-12 | 1994-11-15 | Lifecell | Method of cryopreserving a suspension of biological material |
US5580714A (en) * | 1995-03-08 | 1996-12-03 | Celox Laboratories, Inc. | Cryopreservation solution |
US5601972A (en) * | 1995-03-24 | 1997-02-11 | Organ, Inc. | Long term storage of red cells in unfrozen solution |
US5622867A (en) * | 1994-10-19 | 1997-04-22 | Lifecell Corporation | Prolonged preservation of blood platelets |
US5629145A (en) * | 1995-03-24 | 1997-05-13 | Organ, Inc. | Cryopreservation of cell suspensions |
US5750039A (en) * | 1987-01-30 | 1998-05-12 | Baxter International Inc. | Blood processing systems and methods for collecting mono nuclear cells |
US5750330A (en) * | 1996-06-19 | 1998-05-12 | Litron Laboratories | Method and composition for lyophilizing red blood cells |
US5800978A (en) * | 1992-01-21 | 1998-09-01 | Cobe Laboratories, Inc. | Method of freezing cells and cell-like materials |
US5827640A (en) * | 1996-06-14 | 1998-10-27 | Biostore New Zealand Limited | Methods for the preservation of cells and tissues using trimethylamine oxide or betaine with raffinose or trehalose |
US5897987A (en) * | 1996-03-25 | 1999-04-27 | Advanced Reproduction Technologies, Inc. | Use of arabinogalactan in cell cryopreservation media |
US5919614A (en) * | 1994-10-19 | 1999-07-06 | Lifecell Corporation | Composition comprising three platelet lesion inhibitors for platelet storage |
US5958670A (en) * | 1988-05-18 | 1999-09-28 | Cobe Laboratories, Inc. | Method of freezing cells and cell-like materials |
US6007978A (en) * | 1988-05-18 | 1999-12-28 | Cobe Laboratories, Inc. | Method of freezing cells and cell-like materials |
US6037116A (en) * | 1996-06-14 | 2000-03-14 | Biostore New Zealand, Ltd. | Compositions comprising betaine, sodium citrate and sodium chloride and methods for the preservation of biological materials |
US6045990A (en) * | 1998-07-09 | 2000-04-04 | Baust; John M. | Inclusion of apoptotic regulators in solutions for cell storage at low temperature |
US6059968A (en) * | 1998-01-20 | 2000-05-09 | Baxter International Inc. | Systems for processing and storing placenta/umbilical cord blood |
US6114107A (en) * | 1996-06-14 | 2000-09-05 | Biostore New Zealand Limited | Composition comprising raffinose, TMAO, sodium citrate and methods for the preservation of living tissues |
US6127177A (en) * | 1998-09-11 | 2000-10-03 | Massachusetts Institute Of Technology | Controlled reversible poration for preservation of biological materials |
US6176089B1 (en) * | 1998-10-27 | 2001-01-23 | Modex Th{acute over (e)}rapeutics | Methods and compositions for cryopreservation of cells and tissues |
US6485959B1 (en) * | 1998-10-07 | 2002-11-26 | Cedars Sinai Medical Center | Cell preconditioning and cryopresevation medium |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1305347A (fr) * | 1960-10-14 | 1962-10-05 | Waldhof Zellstoff Fab | Procédé permettant d'obtenir des préparations de cellules vivantes conservables |
IL90188A0 (en) * | 1988-05-18 | 1989-12-15 | Cryopharm Corp | Process and medium for the lyophilization of erythrocytes |
US5045446A (en) * | 1988-08-26 | 1991-09-03 | Cryopharm Corporation | Lyophilization of cells |
JPH02129127A (ja) * | 1988-11-04 | 1990-05-17 | Sumitomo Seika Chem Co Ltd | 改良された赤血球保存液 |
SE466158B (sv) | 1989-04-25 | 1992-01-07 | Migrata Uk Ltd | Analysmetod foer glukosbestaemning i helblod |
IL95912A (en) * | 1989-10-06 | 1998-08-16 | American Nat Red Cross | A method for extending the shelf life of blood cells |
DD288316A5 (de) | 1989-10-11 | 1991-03-28 | Beziksinstitut F. Blutspende- U. Transfusionswesen,De | Verfahren zur regenerierung von gelagerten erythrozytenkonzentraten |
WO1991018504A1 (en) * | 1990-05-25 | 1991-12-12 | Cryopharm Corporation | Process for lyophilizing cells, cell-like materials and platelets in a mixture of biocompatible amphipathic polymers |
ATE157879T1 (de) | 1991-06-14 | 1997-09-15 | Europ Communities | Transformierte erythrozyten, verfahren zu deren herstellung, und ihre verwendung in pharmazeutischen zusammensetzungen |
GB9114202D0 (en) * | 1991-07-01 | 1991-08-21 | Quadrant Holdings Cambridge | Blood products |
IT1261695B (it) * | 1993-06-02 | 1996-05-29 | Sigma Tau Ind Farmaceuti | Impiego di l-carnitina e alcanoil l-carnitine nella conservazione del sangue per trasfusioni e soluzioni stabilizzatrici che le contengono. |
US5891617A (en) | 1993-09-15 | 1999-04-06 | Organogenesis Inc. | Cryopreservation of harvested skin and cultured skin or cornea equivalents by slow freezing |
US6221669B1 (en) | 1994-10-19 | 2001-04-24 | Lifecell Corporation | Prolonged preservation of blood platelets |
US5789151A (en) | 1997-05-15 | 1998-08-04 | The Regents Of The University Of California | Prolonged cold storage of red blood cells by oxygen removal and additive usage |
GB2330516A (en) | 1997-10-22 | 1999-04-28 | Elizabeth Acton | Cryopreservation of cell suspensions |
ATE316757T1 (de) | 1998-05-26 | 2006-02-15 | Lifecell Corp | Cryokonservierung menschlicher roter blutzellen |
US6267925B1 (en) | 1998-12-07 | 2001-07-31 | Haemonetics Corporation | Method for cryopreservation and recovery of red blood cells |
-
1999
- 1999-05-26 AT AT99925899T patent/ATE316757T1/de not_active IP Right Cessation
- 1999-05-26 DE DE69929691T patent/DE69929691T2/de not_active Expired - Lifetime
- 1999-05-26 CA CA002332986A patent/CA2332986C/en not_active Expired - Lifetime
- 1999-05-26 WO PCT/US1999/011674 patent/WO1999060849A1/en active IP Right Grant
- 1999-05-26 JP JP2000550327A patent/JP2002516254A/ja active Pending
- 1999-05-26 ES ES99925899T patent/ES2257050T3/es not_active Expired - Lifetime
- 1999-05-26 AU AU42097/99A patent/AU758703C/en not_active Expired
- 1999-05-26 EP EP99925899A patent/EP1082006B1/de not_active Expired - Lifetime
-
2006
- 2006-01-18 US US11/334,950 patent/US20060127375A1/en not_active Abandoned
-
2012
- 2012-02-08 US US13/368,460 patent/US8895236B2/en not_active Expired - Fee Related
Patent Citations (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4054488A (en) * | 1975-08-14 | 1977-10-18 | Marbach Edward P | Preservation of glucose in blood samples |
US4018911A (en) * | 1975-11-10 | 1977-04-19 | The United States Of America As Represented By The Secretary Of The Navy | Method for large volume freezing and thawing of packed erythrocytes |
US4004975A (en) * | 1975-12-30 | 1977-01-25 | The United States Of America As Represented By The Secretary Of The Navy | Method of isolating and cryopreserving human white cells from whole blood |
US4327799A (en) * | 1979-06-18 | 1982-05-04 | Helmholtz-Institut Fur Biomedizinische Technik | Process and apparatus for freezing living cells |
US4531373A (en) * | 1984-10-24 | 1985-07-30 | The Regents Of The University Of California | Directional solidification for the controlled freezing of biomaterials |
US4774088A (en) * | 1986-01-08 | 1988-09-27 | The United States Of America As Represented By The Deptment Of Health And Human Services | Method and additives for improving the quality and shelf life of stored blood |
US4812310A (en) * | 1986-08-29 | 1989-03-14 | Toru Sato | Preserving solution for blood or packed blood cells and method for preserving blood or packed blood cells by using the same |
US5750039A (en) * | 1987-01-30 | 1998-05-12 | Baxter International Inc. | Blood processing systems and methods for collecting mono nuclear cells |
US6007978A (en) * | 1988-05-18 | 1999-12-28 | Cobe Laboratories, Inc. | Method of freezing cells and cell-like materials |
US5958670A (en) * | 1988-05-18 | 1999-09-28 | Cobe Laboratories, Inc. | Method of freezing cells and cell-like materials |
US5309723A (en) * | 1989-02-08 | 1994-05-10 | The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland | Method of freezing red blood cells |
US5043261A (en) * | 1989-04-10 | 1991-08-27 | Cryopharm Corporation | Lyophilized and reconstituted red blood cell and hemosome compositions |
US5153004A (en) * | 1989-06-02 | 1992-10-06 | Cryopharm Corporation | Freezing and thawing of erythrocytes |
US5118512A (en) * | 1990-01-23 | 1992-06-02 | Osteotech, Inc. (A Delaware Corp.) | Process for cryopreserving biological materials and materials prepared thereby |
US6194136B1 (en) * | 1990-09-12 | 2001-02-27 | Lifecell Corporation | Cryoprotective solutions comprising DMSO, PG, 2,3-butanediol,raffinose and PVP |
US5364756A (en) * | 1990-09-12 | 1994-11-15 | Lifecell | Method of cryopreserving a suspension of biological material |
US5780295A (en) * | 1990-09-12 | 1998-07-14 | Life Cell Corporation | Apparatus for cryopreparation, dry stabilization and rehydration of biological suspensions |
US5242792A (en) * | 1991-02-25 | 1993-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Method for the preservation of red blood cells by lyophilization using glycerol or inositol with disaccharides |
US5800978A (en) * | 1992-01-21 | 1998-09-01 | Cobe Laboratories, Inc. | Method of freezing cells and cell-like materials |
US5919614A (en) * | 1994-10-19 | 1999-07-06 | Lifecell Corporation | Composition comprising three platelet lesion inhibitors for platelet storage |
US5622867A (en) * | 1994-10-19 | 1997-04-22 | Lifecell Corporation | Prolonged preservation of blood platelets |
US5580714A (en) * | 1995-03-08 | 1996-12-03 | Celox Laboratories, Inc. | Cryopreservation solution |
US5759764A (en) * | 1995-03-08 | 1998-06-02 | Celox Laboratories, Inc. | Cryopreservation solution |
US5601972A (en) * | 1995-03-24 | 1997-02-11 | Organ, Inc. | Long term storage of red cells in unfrozen solution |
US5629145A (en) * | 1995-03-24 | 1997-05-13 | Organ, Inc. | Cryopreservation of cell suspensions |
US5897987A (en) * | 1996-03-25 | 1999-04-27 | Advanced Reproduction Technologies, Inc. | Use of arabinogalactan in cell cryopreservation media |
US5827640A (en) * | 1996-06-14 | 1998-10-27 | Biostore New Zealand Limited | Methods for the preservation of cells and tissues using trimethylamine oxide or betaine with raffinose or trehalose |
US6037116A (en) * | 1996-06-14 | 2000-03-14 | Biostore New Zealand, Ltd. | Compositions comprising betaine, sodium citrate and sodium chloride and methods for the preservation of biological materials |
US6114107A (en) * | 1996-06-14 | 2000-09-05 | Biostore New Zealand Limited | Composition comprising raffinose, TMAO, sodium citrate and methods for the preservation of living tissues |
US5750330A (en) * | 1996-06-19 | 1998-05-12 | Litron Laboratories | Method and composition for lyophilizing red blood cells |
US6059968A (en) * | 1998-01-20 | 2000-05-09 | Baxter International Inc. | Systems for processing and storing placenta/umbilical cord blood |
US6045990A (en) * | 1998-07-09 | 2000-04-04 | Baust; John M. | Inclusion of apoptotic regulators in solutions for cell storage at low temperature |
US6127177A (en) * | 1998-09-11 | 2000-10-03 | Massachusetts Institute Of Technology | Controlled reversible poration for preservation of biological materials |
US6485959B1 (en) * | 1998-10-07 | 2002-11-26 | Cedars Sinai Medical Center | Cell preconditioning and cryopresevation medium |
US6176089B1 (en) * | 1998-10-27 | 2001-01-23 | Modex Th{acute over (e)}rapeutics | Methods and compositions for cryopreservation of cells and tissues |
Cited By (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090035289A1 (en) * | 2005-09-26 | 2009-02-05 | Lifecell Corporation | Dry platelet composition |
US10179150B2 (en) | 2005-09-26 | 2019-01-15 | Lifecell Corporation | Dry platelet composition |
US20100255524A1 (en) * | 2007-05-31 | 2010-10-07 | Qiagen Gmbh | Method for stabilising a biological sample |
US8372637B2 (en) * | 2007-05-31 | 2013-02-12 | Qiagen, Gmbh | Method for stabilising a biological sample |
US20100272782A1 (en) * | 2007-07-10 | 2010-10-28 | Owens Rick T | Acellular tissue matrix compositions for tissue repair |
US9382422B2 (en) | 2007-07-10 | 2016-07-05 | Lifecell Corporation | Acellular tissue matrix compositions for tissue repair |
US10406260B2 (en) | 2007-07-10 | 2019-09-10 | Lifecell Corporation | Acellular tissue matrix composition for tissue repair |
US8735054B1 (en) | 2008-01-04 | 2014-05-27 | Lifecell Corporation | Acellular tissue matrix preservation solution |
US8871434B2 (en) | 2008-03-21 | 2014-10-28 | Fenwal, Inc. | Red blood cell storage medium for extended storage |
US20110117647A1 (en) * | 2008-03-21 | 2011-05-19 | Fenwal, Inc. | Red Blood Cell Storage Medium For Extended Storage |
US20090239208A1 (en) * | 2008-03-21 | 2009-09-24 | Veronique Mayaudon | Red Blood Cell Storage Medium For Extended Storage |
US8968992B2 (en) | 2008-03-21 | 2015-03-03 | Fenwal, Inc. | Red blood cell storage medium for extended storage |
US10022473B2 (en) | 2008-06-06 | 2018-07-17 | Lifecell Corporation | Elastase treatment of tissue matrices |
US20090306790A1 (en) * | 2008-06-06 | 2009-12-10 | Wendell Sun | Elastase Treatment of Tissue Matrices |
US9259511B2 (en) | 2008-06-06 | 2016-02-16 | Lifecell Corporation | Elastase treatment of tissue matrices |
US10850007B2 (en) | 2008-06-06 | 2020-12-01 | Lifecell Corporation | Elastase treatment of tissue matrices |
US10413636B2 (en) | 2008-08-14 | 2019-09-17 | Kci Licensing, Inc. | Tissue scaffolds |
US20100040687A1 (en) * | 2008-08-14 | 2010-02-18 | Kci Licensing, Inc. | Tissue Scaffolds |
US9421306B2 (en) | 2008-11-21 | 2016-08-23 | Lifecell Corporation | Reinforced biologic material |
US8333803B2 (en) | 2008-11-21 | 2012-12-18 | Lifecell Corporation | Reinforced biologic material |
US9150318B1 (en) | 2009-01-02 | 2015-10-06 | Lifecell Corporation | Method for sterilizing an acellular tissue matrix |
US10906679B1 (en) | 2009-01-02 | 2021-02-02 | Lifecell Corporation | Method for preparing collagen-based materials |
US10322835B1 (en) | 2009-01-02 | 2019-06-18 | Lifecell Corporation | Method for preparing collagen-based materials |
US9409128B2 (en) | 2009-10-23 | 2016-08-09 | Fenwal, Inc. | Methods for storing red blood cell products |
US11864553B2 (en) | 2009-10-23 | 2024-01-09 | Fenwal, Inc. | Methods and systems for providing red blood cell products with reduced plasma |
US9943077B2 (en) | 2009-10-23 | 2018-04-17 | Fenwal, Inc. | Methods for storing red blood cell products |
US8784499B2 (en) | 2010-03-25 | 2014-07-22 | Lifecell Corporation | Preparation of regenerative tissue scaffolds |
US20110238186A1 (en) * | 2010-03-25 | 2011-09-29 | Lifecell Corporation | Preparation of regenerative tissue scaffolds |
US9206442B2 (en) | 2011-04-28 | 2015-12-08 | Lifecell Corporation | Method for enzymatic treatment of tissue products |
US9957477B2 (en) | 2011-04-28 | 2018-05-01 | Lifecell Corporation | Method for enzymatic treatment of tissue products |
US10207025B2 (en) | 2011-04-28 | 2019-02-19 | Lifecell Corporation | Method for enzymatic treatment of tissue products |
US9238793B2 (en) | 2011-04-28 | 2016-01-19 | Lifecell Corporation | Method for enzymatic treatment of tissue products |
US9956316B2 (en) | 2011-04-28 | 2018-05-01 | Lifecell Corporation | Method for enzymatic treatment of tissue products |
US11957814B2 (en) | 2011-05-31 | 2024-04-16 | Lifecell Corporation | Adipose tissue matrices |
US10159722B2 (en) | 2012-03-08 | 2018-12-25 | Lifecell Corporation | Enzyme-activated collagen and tissue matrices |
US9592278B2 (en) | 2012-03-08 | 2017-03-14 | Lifecell Corporation | Enzyme-activated collagen and tissue matrices |
US10363343B2 (en) | 2012-07-05 | 2019-07-30 | Lifecell Corporation | Tissue-based drain manifolds |
US10758336B2 (en) | 2012-07-06 | 2020-09-01 | Lifecell Corporation | Decellularized muscle matrix |
US11090338B2 (en) | 2012-07-13 | 2021-08-17 | Lifecell Corporation | Methods for improved treatment of adipose tissue |
US10709810B2 (en) | 2012-09-26 | 2020-07-14 | Lifecell Corporation | Processed adipose tissue |
US9370536B2 (en) | 2012-09-26 | 2016-06-21 | Lifecell Corporation | Processed adipose tissue |
US9592254B2 (en) | 2013-02-06 | 2017-03-14 | Lifecell Corporation | Methods for localized modification of tissue products |
US10568988B2 (en) | 2013-02-06 | 2020-02-25 | Lifecell Corporation | Methods for localized modification of tissue products |
US10307510B2 (en) | 2013-11-04 | 2019-06-04 | Lifecell Corporation | Methods of removing alpha-galactose |
WO2017013664A1 (en) * | 2015-07-22 | 2017-01-26 | Ramot At Tel-Aviv University Ltd. | Article of manufacture and methods for increasing survival of red blood cells |
US10850008B2 (en) | 2015-12-11 | 2020-12-01 | Lifecell Corporation | Methods and systems for stiffening of tissue for improved processing |
US10792394B2 (en) | 2016-06-03 | 2020-10-06 | Lifecell Corporation | Methods for localized modification of tissue products |
US11045583B2 (en) | 2016-12-22 | 2021-06-29 | Lifecell Corporation | Devices and methods for tissue cryomilling |
US10413634B2 (en) | 2017-01-30 | 2019-09-17 | Lifecell Corporation | Transglutaminase treated products |
US11724004B2 (en) | 2017-01-30 | 2023-08-15 | Lifecell Corporation | Transglutaminase treated products |
US10940184B2 (en) | 2017-01-30 | 2021-03-09 | Lifecell Corporation | Tissue matrix materials and enzymatic adhesives |
US11110201B2 (en) | 2017-01-30 | 2021-09-07 | Lifecell Corporation | Devices including muscle matrix and methods of production and use |
US10814033B2 (en) | 2017-01-30 | 2020-10-27 | Lifecell Corporation | Transglutaminase treated products |
US11123375B2 (en) | 2017-10-18 | 2021-09-21 | Lifecell Corporation | Methods of treating tissue voids following removal of implantable infusion ports using adipose tissue products |
US10821205B2 (en) | 2017-10-18 | 2020-11-03 | Lifecell Corporation | Adipose tissue products and methods of production |
US11246994B2 (en) | 2017-10-19 | 2022-02-15 | Lifecell Corporation | Methods for introduction of flowable acellular tissue matrix products into a hand |
US11826488B2 (en) | 2017-10-19 | 2023-11-28 | Lifecell Corporation | Flowable acellular tissue matrix products and methods of production |
US20220033765A1 (en) * | 2019-04-19 | 2022-02-03 | Fujifilm Wako Pure Chemical Corporation | Storage stabilizer for extracellular vesicle and storage stabilization method for extracellular vesicle |
CN113710794A (zh) * | 2019-04-19 | 2021-11-26 | 富士胶片和光纯药株式会社 | 细胞外囊泡的保存稳定化剂及保存稳定化方法 |
US11633521B2 (en) | 2019-05-30 | 2023-04-25 | Lifecell Corporation | Biologic breast implant |
CN114786481A (zh) * | 2019-11-29 | 2022-07-22 | 新泽西鲁特格斯州立大学 | 用于储存血液制品的组合物、试剂盒和方法及其使用方法 |
WO2021108806A1 (en) * | 2019-11-29 | 2021-06-03 | Rutgers, The State University Of New Jersey | Compositions, kits and methods for storage of blood products and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
JP2002516254A (ja) | 2002-06-04 |
EP1082006B1 (de) | 2006-02-01 |
ES2257050T3 (es) | 2006-07-16 |
US8895236B2 (en) | 2014-11-25 |
AU758703B2 (en) | 2003-03-27 |
US20120141974A1 (en) | 2012-06-07 |
ATE316757T1 (de) | 2006-02-15 |
DE69929691D1 (de) | 2006-04-13 |
CA2332986A1 (en) | 1999-12-02 |
AU758703C (en) | 2004-06-03 |
EP1082006A4 (de) | 2002-09-11 |
AU4209799A (en) | 1999-12-13 |
EP1082006A1 (de) | 2001-03-14 |
DE69929691T2 (de) | 2006-09-07 |
WO1999060849A1 (en) | 1999-12-02 |
CA2332986C (en) | 2009-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8895236B2 (en) | Composition for cryopreservation comprising nicotinamide, glycerol and red blood cells | |
Zimrin et al. | Current issues relating to the transfusion of stored red blood cells | |
Hess | Red cell changes during storage | |
US4920044A (en) | Intracellular flush solution for preserving organs | |
US5800978A (en) | Method of freezing cells and cell-like materials | |
CA2598366C (en) | Compositions and methods for the storage of red blood cells | |
US9314014B2 (en) | Compositions and methods for the storage of red blood cells | |
US6007978A (en) | Method of freezing cells and cell-like materials | |
Quinones et al. | Organ protective mechanisms common to extremes of physiology: a window through hibernation biology | |
Taylor | Biology of cell survival in the cold: the basis for biopreservation of tissues and organs | |
Gurevitch et al. | Aprotinin improves myocardial recovery after ischemia and reperfusion:: Effects of the drug on isolated rat hearts | |
US5958670A (en) | Method of freezing cells and cell-like materials | |
Ackemann et al. | Celsior versus custodiol: early postischemic recovery after cardioplegia and ischemia at 5 C | |
Wagner et al. | Biochemical stabilization enhances red blood cell recovery and stability following cryopreservation | |
Olbertz et al. | Use of modified Custodiol-N as perfusion solution in ex vivo lung perfusion | |
EP0664953B1 (de) | Lungentransplantat-Konservierungsmittelmischung und Verfahren zur Lebendkonservierung von Lungentransplantaten | |
Rittmeyer et al. | Influence of the Cryoprotective Agents Glycerol and Hydroxyethyl Starch on Red Blood Cell ATP and 2, 3‐Diphosphoglyceric Acid Levels | |
Galiñanes et al. | Effect of sodium aspartate on the recovery of the rat heart from long-term hypothermic storage | |
Bhayana et al. | Beneficial effects of fluosol–polyethylene glycol cardioplegia on cold, preserved rabbit heart | |
KR100304594B1 (ko) | 이식용 장기 및 혈액세포 보존제의 조성물 | |
RU2438698C1 (ru) | Водорастворимая композиция, обладающая свойствами кардиопротектора | |
CR et al. | Survival and function of preserved RBC and preserved platelets | |
Korsak et al. | Evaluation of two distinct cryoprotectants for cryopreservation of human red blood cell concentrates | |
Hochhauser et al. | Effect of experimental cardioplegia methods on normal and hypertrophied rat hearts | |
Karow Jr | Biological Effects of Cryoprotectant Perfusion, Delivery and Removal to Nonfrozen Organs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BANK OF AMERICA, N.A., ILLINOIS Free format text: SECURITY AGREEMENT;ASSIGNOR:LIFECELL CORPORATION;REEL/FRAME:021006/0830 Effective date: 20080519 |
|
AS | Assignment |
Owner name: LIFECELL CORPORATION, TEXAS Free format text: PATENT RELEASE;ASSIGNOR:BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT;REEL/FRAME:027181/0404 Effective date: 20111104 |
|
AS | Assignment |
Owner name: BANK OF AMERICA, N.A., AS COLLATERAL AGENT, NORTH Free format text: SECURITY AGREEMENT;ASSIGNORS:KCI LICENSING, INC.;LIFECELL CORPORATION;TECHNIMOTION, LLC;REEL/FRAME:027185/0174 Effective date: 20111104 |
|
AS | Assignment |
Owner name: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATE Free format text: SECURITY AGREEMENT;ASSIGNORS:KCI LICENSING, INC.;LIFECELL CORPORATION;TECHNIMOTION, LLC;REEL/FRAME:027194/0447 Effective date: 20111104 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: LIFECELL CORPORATION, TEXAS Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST;REEL/FRAME:040098/0200 Effective date: 20160920 Owner name: KCI LICENSING, INC., TEXAS Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST;REEL/FRAME:040098/0200 Effective date: 20160920 Owner name: KINETIC CONCEPTS, INC., TEXAS Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST;REEL/FRAME:040098/0200 Effective date: 20160920 Owner name: TECHNIMOTION, LLC, TEXAS Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST;REEL/FRAME:040098/0200 Effective date: 20160920 |
|
AS | Assignment |
Owner name: LIFECELL CORPORATION, TEXAS Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BANK OF AMERICA, N.A.;REEL/FRAME:041143/0361 Effective date: 20170131 |